Molecular Subtype
Triple-Negative Breast Carcinoma
CI-CAN-00008567TNBCExplore in graph →
417 active trials3 approved drugs8 evidence items
Loading cancer entity…
Loading cancer entity…
Molecular Subtype
CI-CAN-00008567TNBCExplore in graph →
Clinical trials
950 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (168)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05318469 | Ivermectin in Combination With Balstilimab or Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancer | recruiting | Phase 1 / Phase 2 | 34 | Yuan YuanOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT05812807 | Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab | recruiting | Phase 3 | 1,295 | Alliance for Clinical Trials in OncologyOTHER | 3 | Aug 5, 2026 |
| NCT07178730 | NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast Cancer(ADAPT-TN-IV) | not yet recruiting | Phase 3 | 765 | Women's Cancer Study Group GmbHOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT07552181 | Phase II Trial of Pembrolizumab/Chemotherapy With Live Biotherapeutic Product MO-03 in Patients With Early Stage Triple Negative Breast Cancer | not yet recruiting | Phase 2 | 50 | Yuan YuanOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT03742102 | A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer(BEGONIA) | active not recruiting | Phase 1 / Phase 2 | 243 | AstraZenecaINDUSTRY | 6 | Aug 4, 2026 | clinicaltrials |
| NCT05579366 | Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)(RAINFOL-01) | recruiting | Phase 1 / Phase 2 | 884 | GenmabINDUSTRY | 3 | Aug 4, 2026 | clinicaltrials |
| NCT07017673 | Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer | recruiting | Phase 2 | 34 | Cedars-Sinai Medical CenterOTHER | 1 | Aug 4, 2026 | clinicaltrials |
| NCT07078604 | A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer | recruiting | Phase 2 | 20 | University of WashingtonOTHER | 1 | Aug 4, 2026 | clinicaltrials |
| NCT07739485 | Paclitaxel Oral Solution in Triple Neagtive Breast Cancer Neoadjuvant Therapy: A Dose-Finding Study(GBCF003) | recruiting | Phase 1 / Phase 2 | 30 | Liu ShuOTHER | 1 | Aug 4, 2026 | clinicaltrials |
| NCT07743632 | Neoadjuvant Angiogenesis-Targeting Bispecific Chemoimmunotherapy for TNBC(NeoASPECT) | not yet recruiting | Phase 2 | 110 | University of Kansas Medical CenterOTHER | 0 | Aug 4, 2026 | clinicaltrials |
| NCT03077776 | Tracking Triple-negative Breast Cancer Evolution Through Therapy(TRACERX-TNBC) | active not recruiting | N/A | 149 | UNICANCEROTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT06081244 | NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III)(ADAPT-TN-III) | recruiting | Phase 3 | 348 | Women's Cancer Study Group GmbHOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT07151586 | Testing Two Different Drugs (Sacituzumab-govitecan and Trastuzumab-deruxtecan) Combinations Prescribed in an Alterning Pattern to Patients With Metastatic or Locally Advanced Triple-negative Breast Cancer(ALTER) | not yet recruiting | Phase 2 | 260 | UNICANCEROTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT04052555 | Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer | active not recruiting | Phase 1 | 42 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
| NCT04345913 | Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer | active not recruiting | Phase 1 / Phase 2 | 24 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
| NCT04491942 | Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer | active not recruiting | Phase 1 | 74 | National Cancer Institute (NCI)NIH | 2 | Jul 31, 2026 | clinicaltrials |
| NCT06419621 | PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBC | active not recruiting | Phase 3 | 392 | Biotheus Inc.INDUSTRY | 1 | Jul 29, 2026 | clinicaltrials |
| NCT06562192 | Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers | recruiting | Phase 1 | 162 | Novartis PharmaceuticalsINDUSTRY | 10 | Jul 29, 2026 | clinicaltrials |
| NCT07229417 | A Trial Evaluating the Efficacy of Ivonescimab in Metastatic Endocrine Refractory HR-positive HER2-negative or Triple Negative Invasive Lobular Carcinoma | recruiting | Phase 2 | 29 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT06150664 | A Phase 1 of CTX-8371 in Patients With Advanced Malignancies | recruiting | Phase 1 | 85 | Compass TherapeuticsINDUSTRY | 1 | Jul 28, 2026 | clinicaltrials |
| NCT06347068 | Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells | recruiting | Phase 1 | 42 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT02445391 | Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy | active not recruiting | Phase 3 | 415 | ECOG-ACRIN Cancer Research GroupNETWORK | 2 | Jul 27, 2026 | clinicaltrials |
| NCT03915678 | Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors(AGADIR) | active not recruiting | Phase 2 | 247 | Institut BergoniéOTHER | 1 | Jul 24, 2026 | clinicaltrials |
| NCT06078384 | Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBC(ETNA) | recruiting | Phase 2 | 354 | UNICANCEROTHER | 2 | Jul 24, 2026 | clinicaltrials |
| NCT07458113 | Sac-TMT for Active TNBC Brain Metastases(BERLIN) | not yet recruiting | Phase 2 | 20 | Yale UniversityOTHER | 1 | Jul 24, 2026 | clinicaltrials |
| NCT05455658 | STEMVAC in Patients With Early Stage Triple Negative Breast Cancer | active not recruiting | Phase 2 | 33 | University of WashingtonOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT06225505 | Early Detection of Triple Negative Breast Cancer Relapse (CUPCAKE)(CUPCAKE) | recruiting | N/A | 450 | Institut CurieOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT06382142 | A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer(PANKU-Breast02) | active not recruiting | Phase 3 | 418 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 23, 2026 | clinicaltrials |
| NCT06471205 | A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Unresectable Locally Advanced or Recurrent Metastatic Triple-negative Breast Cancer | recruiting | Phase 2 | 52 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 23, 2026 | clinicaltrials |
| NCT06606730 | Personalizing the Use of Pembrolizumab for Patients Who Have a Strong Response in Early Triple Negative Breast Cancer(OPT-PEMBRO) | recruiting | Phase 3 | 2,454 | UNICANCEROTHER | 2 | Jul 23, 2026 | clinicaltrials |
| NCT07721259 | A Vaccine (STEMVAC) for Improving Survival in Patients With Triple-Negative Breast Cancer and Moderate or Extensive Residual Cancer Burden | not yet recruiting | Phase 2 | 60 | University of WashingtonOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT05208762 | A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors | recruiting | Phase 1 | 714 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 11 | Jul 22, 2026 | clinicaltrials |
| NCT06157892 | A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors | active not recruiting | Phase 2 | 54 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 10 | Jul 22, 2026 | clinicaltrials |
| NCT07318805 | A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 260 | PfizerINDUSTRY | 1 | Jul 22, 2026 | clinicaltrials |
| NCT04348747 | Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer | recruiting | Phase 2 | 23 | Roswell Park Cancer InstituteOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT05552001 | Safety and Efficacy Analysis of an Antibody Associated With a Chemotherapy for Patients With a Triple Negative Metastatic Breast Cancer(ISIdE) | active not recruiting | Phase 3 | 96 | UNICANCEROTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT04230109 | Sacituzumab Govitecan In TNBC(NeoSTAR) | recruiting | Phase 2 | 239 | Massachusetts General HospitalOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT05078047 | Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO(MOIO) | active not recruiting | Phase 3 | 646 | UNICANCEROTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT07064018 | Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies | recruiting | Phase 1 / Phase 2 | 67 | University of California, IrvineOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT02276443 | Molecular Testing and Imaging in Improving Response in Patients With Stage I-III Triple-Negative Breast Cancer Receiving Chemotherapy MDACC Breast Moonshot Initiative | active not recruiting | N/A | 798 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT02411656 | Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy | active not recruiting | Phase 2 | 71 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT07258563 | The TASTY-steering Study(TASTY-steering) | recruiting | N/A | 201 | University Medical Center GroningenOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT07705438 | Granzyme B-PET: Predicting Immunotherapy Efficacy in TNBC | recruiting | — | 30 | Fudan UniversityOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT01116648 | Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer | active not recruiting | Phase 1 / Phase 2 | 155 | National Cancer Institute (NCI)NIH | 1 | Jul 14, 2026 | clinicaltrials |
| NCT04443348 | Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD) | active not recruiting | Phase 2 | 120 | Laura M. Spring, MDOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT06976944 | Pembrolizumab + Paclitaxel +/- Bevacizumab for Triple-negative Breast Cancer(PRELUDE) | recruiting | Phase 2 | 24 | Yukinori OzakiOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT07137416 | Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer | recruiting | Phase 1 | 36 | National Cancer Institute (NCI)NIH | 1 | Jul 13, 2026 | clinicaltrials |
| NCT05101096 | Study of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors(ASCENT-J02) | active not recruiting | Phase 1 / Phase 2 | 135 | Gilead SciencesINDUSTRY | 1 | Jul 10, 2026 | clinicaltrials |
| NCT07570524 | Predicting Response to Immunochemotherapy in Early Triple Negative Breast Cancer(PRIME-TNBC) | recruiting | — | 200 | Center Eugene MarquisOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT07681297 | Tislelizumab in Combination With Bevacizumab and Capecitabine in Advanced Solid Tumors With Evaluation in Immunotherapy-Resistant and Central Nervous System Disease(TIBEC) | not yet recruiting | Phase 1 / Phase 2 | 154 | National University Hospital, SingaporeOTHER | 1 | Jul 10, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Aug 5, 2026source: clinicaltrials